Exelixis says lawsuit arises from MSN’s further amendment of its abbreviated new drug application, originally filed with the FDA in 2019 for a generic version of Cabometyx (cabozantinib) tablets.
- Says MSN’s ANDA now requests approval to market a generic version prior to expiration of Exelixis’ patent
- NOTE: June 23,
Exelixis’ Latest Cabometyx Patent Suit Is Down to Validity
NOTE
- Exelixis Inc. shares were little changed in postmarket trading as of 5:32 p.m. New York time
- The average 12-month price target of $27.08 is 24.0% above the current price
- 11 buys, 2 sells, 2 holds
To view the source of this ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.